Glenmark Pharma Soars on $1.9 Billion Licensing Deal with AbbVie

Glenmark Pharma surged 10% on July 11 after its subsidiary signed a $1.9 billion global licensing deal with AbbVie for cancer drug ISB 2001. The agreement grants AbbVie exclusive rights across major markets, while Glenmark leads in emerging regions. Analysts call it India’s largest pharma licensing deal to date.